On the other hand, AT1R blockade improved endothelial function after MS and this effect was maintained for up to 60 min, providing evidence that the Ang II-AT1R pathway is implicated in the transient endothelial function observed after MS. Here, AGTR1 is linked to myeloid sarcoma.